BlueWind Medical Announces New Executive Appointments

PARK CITY, Utah and HERZLIYA, Israel, Nov. 1, 2022 /PRNewswire/ -- BlueWind Medical, Ltd., a medical device company transforming neuromodulation therapy for overactive bladder (OAB), announced three executive appointments to leadership positions within the company. Seasoned medical device industry expert Seamus O'Connor joins as Vice President of Quality, Paul Maguire joins as Vice President of Operations, and Asher Kuper brings vast Medtech credentials as the Vice President of Research and Development, adding more than two decades of operational expertise.

"This group of talented professionals bring mature and multinational company experience," said Dan Lemaitre, Chairman and CEO of BlueWind Medical. "We could not be more eager to welcome them to BlueWind Medical. Together, I believe their passion and leadership will strengthen our ability to revolutionize neuromodulation therapy for overactive bladder, driving continued value for our stakeholders and the patients we hope to serve."

Seamus O'Connor brings 23 years of experience in the medical device industry across quality assurance and regulatory affairs, working with various medical device technologies. His product experience includes life-supporting and sustaining devices, as well as sterile, implantable, and consumable devices. He has successfully managed numerous U.S. Food and Drug Administration inspections and other audits by regulatory bodies. Prior to BlueWind Medical, Seamus held positions of increasing responsibility at MEDNOVA, TE Connectivity, Boston Scientific and Natus Medical. Seamus holds a Bachelor of Engineering degree and a Higher Diploma in Quality Management from the University of Galway, Ireland.

Asher Kuper has held various roles within startups and global companies across the Medtech industry for the past 18 years. He recently served as Vice President of Product for Zebra Medical Vision (acquired by Nanox Vision), where he was responsible for the strategic roadmap of organic and joint ventures product management, and as CEO of SpirCare, where he helped pioneer approaches to respiratory disease management based on artificial intelligence. Asher holds a Master of Business Administration and a Bachelor of Science degree in biomedical engineering from Tel Aviv University.

Paul Maguire brings more than 25 years of operations experience in medical devices to BlueWind Medical, with a career spanning multinational organizations such as Stryker, Boston Scientific, Medtronic, Allergan and, most recently, AbbVie. As Executive Director of New Jersey Operations at AbbVie, Paul led a large-scale regenerative medicine business and oversaw major operational transformation programs. Before that, he also managed a startup operation and supply chain for the VenaSeal delivery system for the treatment of varicose veins, supporting the global sales team within Europe, Canada and the U.S., following the successful completion of a premarket approval application. He holds a Bachelor of Engineering from the Dundalk Institute of Technology and a Master of Business Administration from the Athlone Institute of Technology.

Overactive bladder causes a frequent and urgent need to empty your bladder. According to the National Association for Continence, OAB is a chronic, debilitating condition affecting over 33 million Americans. OAB can manifest in urgency urinary incontinence, the involuntary leakage of urine associated with a sudden compelling desire to void. OAB is a highly prevalent condition among men and women, with approximately 23% of U.S. adults affected.ⁱ

BlueWind Medical is an innovative medical device company that is transforming neuromodulation therapy for the treatment of overactive bladder. BlueWind Medical has developed a miniature tibial neuromodulation solution for OAB that is implanted in the ankle region in a minimally invasive outpatient procedure under local anesthesia. The patient-centric system allows for therapy customization to enhance patient response and includes a lightweight wearable device that fits around the ankle. Our pivotal study (OASIS) that is being conducted under an Investigational Device Exemption (IDE) from the FDA completed one year follow-up in October 2022. RENOVA iStim is not approved for use in the U.S.

For additional information, please visit BlueWindMedical.com

ⁱ Reynolds, WS et al. The Burden of Overactive Bladder on US Public Health. Curr Bladder Dysfunct Rep. 2016 Mar; 11(1): 8-13. doi:10.1007/s11884-016-0344-9.

SOURCE BlueWind Medical